Neil Weir, Sitryx CEO

Big Phar­ma-backed Sit­ryx locks an ad­di­tion­al $39M in a Se­ries A raise to ad­vance its im­munometa­bol­ic pipeline

Sit­ryx Ther­a­peu­tics has raised an ad­di­tion­al £32 mil­lion ($39 mil­lion) in a fol­low-on to its 2018 Se­ries A to help push its im­munometa­bol­ic pipeline in­to the clin­ic.

New in­vestor Ox­ford Sci­ence En­ter­pris­es (OSE) joins the fray with Big Phar­ma back­ers GSK and Eli Lil­ly, as well as Sofinno­va Part­ners, SV Health In­vestors and Long­wood Fund. The Ox­ford, UK-based com­pa­ny made its de­but in 2018 with a $30 mil­lion Se­ries A, bring­ing its to­tal fundrais­ing to more than $75 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.